In individuals who carried GCKR rs1260326, PNPLA3 rs738409, TM6SF2 rs58542926, and MBOAT7 rs641738 variants (n = 218 NAFLD/445 total) there was a fivefold increased risk of steatosis (OR: 4.97, 95% CI 2.51–9.83) (Di Costanzo et al., 2018). Here, MBOAT7 is linked to metabolic dysfunction-associated steatotic liver disease.